Freenome, Inc. (FRNM)
Nasdaq · Healthcare · Diagnostics & Research
$16.83+3.13%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $1.8B
- 52-week range
- $9.95 – $17.50
- 52-week change
- +53.96%
- EPS (trailing)
- −$2.04
Fiscal year to Dec 2025
- Net income
- $837K
From the company’s annual report on SEC EDGAR.
About Freenome, Inc.
Freenome, Inc., a biotechnology company, develops blood-based screening tests to detect cancer in the United States. The company offers an early cancer detection platform that integrates multiomics, artificial intelligence, and machine learning to uncover complex biological signals associated with cancer. It develops SimpleScreen CRC, a blood-based test, including a test for colorectal cancer screening, as well as tests for multi-cancer and multi-disease detection, such as lung, breast, cervical, liver, pancreatic, and esophageal cancers. The company was founded in 2014 and is headquartered in Brisbane, California.
Headquarters: Brisbane, United States · 375 employees · freenome.com